Skip to content

Single vs split dose of prednisolone in the treatment relapses of childhood nephrotic syndrome: A Randomized Controlled Trial

Single vs split dose of prednisolone in the treatment relapses of childhood Nephrotic syndrome

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2019/025
Enrollment
Unknown
Registered
2019-07-29
Start date
2019-08-14
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotic syndrome

Interventions

1. Study setting The paediatric nephrology section of the Professorial Paediatric Unit at Teaching Hospital Peradeniya 2. Method of randomization Block randomization. Study group and control. Each a

Sponsors

Teaching hospital, Peradeniya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Male and female • Between 1 and 14 years of age • With idiopathic nephrotic syndrome • Admitted to the unit with a relapse

Exclusion criteria

Exclusion criteria: * Patients with steroid resistant nephrotic syndrome * Patients with secondary nephrotic syndrome * Patients who have been started on treatment for the 1st episode/relapse prior to the admission to our unit * Patients with deranged renal functions * Patients with other associated co morbidities * Presented with first episode of nephrotic syndrome

Design outcomes

Primary

MeasureTime frame
Remission is defined as a urine test with nil or trace proteinuria for 3 consecutive days. Urine albumin test will be checked every day only from early morning urine sample for assessment of remission Number of days until a remission will be used to compare the test group and the control group [Daily urine analysis and date of remission (for number of days for remission after introducing the intervention) ]

Secondary

MeasureTime frame
Proportion of patients on second line medicine/s who achieved remissions in < 5 days Proportion of patients not on second line medicine/s who achieved remissions in < 5 days [At study completion]

Countries

Sri Lanka

Contacts

Public ContactDr. Lasanthi Weerasooriya

Senior Registrar in Paediatric Nephrology

weerasooriya.lk@gmail.com

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026